Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Textual)

v3.8.0.1
Summary of Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 01, 2018
Feb. 21, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Restricted Cash and Cash Equivalents, Noncurrent       $ 45,000 $ 45,000
Money Market Funds Fair Value       750,965 1,500,882
Contingent Consideration Funds Fair Value       1,210,000 1,210,000
Deferred Tax Liabilities, Net       $ 183,923 $ 1,525,896
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent       34.00% 34.00%
New Valeant Agreement [Member]          
Revenue Recognition, Milestone Method, Description   the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.      
Proceeds From Upfront Payment   $ 4,000,000      
Accounting Standards Update 2014-09 [Member]          
Cumulative Effect on Retained Earnings, Net of Tax $ 9,500,000        
Jade Therapeutics, Inc [Member]          
Goodwill       $ 1,525,896  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       3,912,314  
Scenario, Plan [Member]          
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent     21.00%    
Department Of Defence And National Science Foundation [Member]          
Revenue from Grants       $ 3,234,000  
Minimum [Member]          
Property, Plant and Equipment, Useful Life       2 years  
Maximum [Member]          
Property, Plant and Equipment, Useful Life       5 years